000			02153cam a2200301 a 4500
003			EG-GiCUC
008			190625s2018 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.12.10.Ph.D.2018.Em.S
100	0		_aEmad Abdullah Deeb
245	1	0	_aSynthesis of some new pyrazoles and their fused derivatives as antitumor agents / _cEmad Abdullah Deeb ; Supervised Nadia Hanafy Metwally
246	1	5	_aتشييد بعض البيرازولات الجديدة ومشتقاتها الملتحمة كمضادات للأورام
260			_aCairo : _bEmad Abdullah Deeb , _c2018
300			_a200 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Science - Department of Organic Chemistry
520			_aThe original work of this thesis includes: The key intermediate 3-aminopyrazolo[4,3-c]pyridine-4,6-dione (2) is considered as a precursor for some novel pyrazolo[4,3-c]pyridines such as 5a-c, 6a-c, arylhydrazopyrazolo[4,3-c]-pyridines 8a-e pyrazolo[4,5,1-ij][1,6] naphthyridines 11a-e, 18a-d and pyrido[4',3':3,4]pyrazolo[1,5-a]-pyrimidines 15a-d, 19a-p through Knovenegal condensation, coupling reaction and Michael addition. The structures were confirmed by elemental analyses, spectral data and all possible have been postulated to account for their formation. Some of the newly synthesized pyrazolo[4,3-c]pyridine derivatives were investigated for anticancer activity. The results of the cytotoxic activity revealed that compound 6b was the most active compound against the breast and liver carcinoma cell lines which gives IC50 values of 1.937 and 3.695 æg/mL, respectively compared to reference drug (doxorubicin) with IC50 values of 2.527 and 4.749 æg/ml, respectively
530			_aIssued also as CD
653		4	_a3-Aminopyrazolo [4,3-c]-pyridine-4,6-dione
653		4	_a3-Cyanomethyl-4-cyano-5-amino-1H-pyrazole
653		4	_aPyrazolo[4,3-c]pyridines
700	0		_aNadia Hanafy Metwally , _eSupervisor
905			_aAsmaa _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c72576 _d72576